Frontiers in Islet Biology and Diabetes (Keystone B3 2018) | InSphero

Frontiers in Islet Biology and Diabetes (Keystone B3 2018)

Feb 04 - 08, 2018

Re-inventing the human islet disease model

jump to section

Join InSphero Islet Microtissue Product Manager Burcak Yesildag and Field Application Scientist Sue Grepper at the Keystone B3 symposium for four days of full immersion into the crucial aspects of islet cell biology.  Drs. Yesildag and Grepper will be available throughout the meeting to discuss how InSphero can help you:

  • Eliminate native islet variability using standardized islet microtissues
  • Expand your assay window with islet microtissues displaying an average 13-fold glucose-stimulated insulin secretion
  • Use a physiologically relevant in vitro model reflecting in vivo dynamics of insulin release and native tissue architecture
  • Stop hand-picking islets!

New Frontiers in Islet Biology with Microfluidics

During the poster session, Dr. Yesildag will present exciting new work using a microfluidic perifusion system that enables insulin release dynamics to be studied at the single islet level. Highlights of the study include:

  • Novel application of InSphero’s microphysiological system facilitated rapid glucose switches and short sampling intervals down to 20 seconds
  • Reaggregated human islets displayed highly reproducible and robust glucose dependent insulin secretion across donors with stable function and viability for more than 28 days
  • In perifusion experiments, the step from 2.8 to 16.7 mM glucose induced biphasic insulin secretion with a prominent first phase (∼35-fold increase) and a sustained, pulsatile second phase (∼8-fold increase) potentiated by the GLP-1 agonist Exendin-4

Conference Detail

  • Conference Dates: February 4-8, 2018